Difference between revisions of "Template:Antiretroviral drug"
Jump to navigation
Jump to search
blackwiki>Whywhenwhohow (Fostemsavir approved) |
m (203 revisions imported) |
||
| (8 intermediate revisions by 3 users not shown) | |||
| Line 11: | Line 11: | ||
* [[Vicriviroc]]<sup>†</sup>, [[Cenicriviroc]]<sup>†</sup>, [[PRO 140]]<sup>†</sup>) | * [[Vicriviroc]]<sup>†</sup>, [[Cenicriviroc]]<sup>†</sup>, [[PRO 140]]<sup>†</sup>) | ||
* ''[[CD4]]'' ([[Ibalizumab]]<sup>†</sup>, [[UB421]]<sup>§</sup>) | * ''[[CD4]]'' ([[Ibalizumab]]<sup>†</sup>, [[UB421]]<sup>§</sup>) | ||
| − | * ''[[gp120]]'' ([[Fostemsavir]] | + | * ''[[gp120]]'' ([[Fostemsavir]]) |
| group2 = [[Reverse-transcriptase inhibitor|Reverse-transcriptase<br /> inhibitors]] (RTIs) | | group2 = [[Reverse-transcriptase inhibitor|Reverse-transcriptase<br /> inhibitors]] (RTIs) | ||
| Line 63: | Line 63: | ||
* [[BI 224436]]<sup>†</sup> | * [[BI 224436]]<sup>†</sup> | ||
* [[Cabotegravir]]<sup>†</sup> | * [[Cabotegravir]]<sup>†</sup> | ||
| − | * [[Bictegravir|Bictegravir (BIC)]] | + | * [[Bictegravir|Bictegravir (BIC)]]° |
* [[MK-2048]]<sup>†</sup> | * [[MK-2048]]<sup>†</sup> | ||
| Line 103: | Line 103: | ||
* [[Darunavir/cobicistat/emtricitabine/tenofovir alafenamide]] | * [[Darunavir/cobicistat/emtricitabine/tenofovir alafenamide]] | ||
* [[Dolutegravir/lamivudine]] | * [[Dolutegravir/lamivudine]] | ||
| + | * [[Dolutegravir/lamivudine/tenofovir]] | ||
* [[Dolutegravir/rilpivirine]] | * [[Dolutegravir/rilpivirine]] | ||
| − | * [[Doravirine/lamivudine/tenofovir | + | * [[Doravirine/lamivudine/tenofovir]] |
* [[Efavirenz/emtricitabine/tenofovir]]°<sup>#</sup> | * [[Efavirenz/emtricitabine/tenofovir]]°<sup>#</sup> | ||
| + | * [[Efavirenz/lamivudine/tenofovir]]<sup>#</sup> | ||
* [[Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide]] | * [[Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide]] | ||
* [[Elvitegravir/cobicistat/emtricitabine/tenofovir]]° | * [[Elvitegravir/cobicistat/emtricitabine/tenofovir]]° | ||
| Line 112: | Line 114: | ||
* [[Emtricitabine/rilpivirine/tenofovir]]° | * [[Emtricitabine/rilpivirine/tenofovir]]° | ||
* [[Emtricitabine/tenofovir]]°<sup>#</sup> | * [[Emtricitabine/tenofovir]]°<sup>#</sup> | ||
| + | * [[Lamivudine/nevirapine/stavudine]]<sup>#</sup> | ||
| + | * [[Lamivudine/nevirapine/zidovudine]]<sup>#</sup> | ||
* [[Lamivudine/raltegravir]] | * [[Lamivudine/raltegravir]] | ||
* [[Lamivudine/tenofovir]] | * [[Lamivudine/tenofovir]] | ||
Latest revision as of 14:24, 22 October 2020
Initial visibility: currently defaults to autocollapse
To set this template's initial visibility, the |state= parameter may be used:
|state=collapsed:{{Antiretroviral drug|state=collapsed}}to show the template collapsed, i.e., hidden apart from its title bar|state=expanded:{{Antiretroviral drug|state=expanded}}to show the template expanded, i.e., fully visible|state=autocollapse:{{Antiretroviral drug|state=autocollapse}}
If the |state= parameter in the template on this page is not set, the template's initial visibility is taken from the |default= parameter in the Collapsible option template. For the template on this page, that currently evaluates to autocollapse.